Allogeneic IBM-SCT improved BOS compared to IV-SCT.

Yoshiko Yamasuji-Maeda (13767344)
Hisakazu Nishimori (13767347)
Keisuke Seike (13767350)
Akira Yamamoto (560236)
Hideaki Fujiwara (6056186)
Taiga Kuroi (13767353)
Kyosuke Saeki (13767356)
Haruko Fujinaga (13767359)
Sachiyo Okamoto (13767362)
Ken-ichi Matsuoka (2311861)
Nobuharu Fujii (219190)
Takehiro Tanaka (7374551)
Masahiro Fujii (2168368)
Katsumi Mominoki (13767365)
Takuro Kanekura (278777)
Yoshinobu Maeda (441679)

Open link

Publication date

September 2022

DOI

10.1371/journal.pone.0273749.g002

Publisher

Public Library of Science (PLoS)

Abstract

(A) B10.BR recipients were conditioned with cyclophosphamide (120 mg/kg/day i.p., on days –3 and –2) and irradiation (8.3 Gy, day –1) prior to reconstitution with 1 × 107 C57BL/6 TCD-BM plus 5×104 splenic T cells. (B) The recipients were analyzed in terms of body weight change and chronic GVHD score after SCT (Syn IV, n = 6; Allo IV, n = 14; Allo IBM, n = 10). Data from two independent experiments were combined. *P P n = 11; Allo IV, n = 11; Allo IBM, n = 11). Data from three independent experiments were combined. # P = 0.105, *P P P n = 7; Allo IV, n = 9; Allo IBM, n = 10). Data from two independent experiments were combined. **P < 0.01. GVHD: graft-versus host disease, SCT: stem cell transplantation, Allo: allogeneic, Syn: syngeneic, IV: ...